Sign in with Google. Opens in new tab
bearish
카켄제약(4521 JP): 상반기 주요 운영 지표 약화, 하반기도 나아지지 않아
392 Views28 Nov 2023 11:15
This page has been machine-translated. Click here to revert to original page
요약
- Kaken Pharmaceutical (4521 JP) reported 2% YoY decline in revenue H1FY24, while operating profit decreased 33% YoY. Top selling products are impacted by NHI drug price revision and increasing competition.
- The company has reiterated FY24 guidance of flat revenue, 5% YoY decline in operating profit, and 23% YoY growth in net profit. Profitability is expected to deteriorate in H2.
- Kaken is not expected to see any immediate respite as the small contribution from the new products will not compensate for the revenue loss from its top selling products.
관련 통찰력
More »Loading
인기 컬렉션
More »트렌드 통찰력
More »- Gold Miners ETF (GDX US): Big Outperformance Driven by Benchmark Change; Valuation Gap Opens Up
- Quiddity Leaderboard STAR 50/100 Sep25: Final Expectations; New Pair Trades
- China A50 ETFs Rebalance Preview: Three Changes in September
- Sun Corp (6736) - CLBT Has Round-Tripped, But Now Better ParentCo and a Buyback so Set-Up Is Better
- Kangji Medical (9997 HK): TPG/QIA/Founder's Offer Is No Knockout
최고의 유료화되지 않은 통찰력
More »- Tradesmen's Collective: Fixing the Trades with Tech, Transparency & Boots-on-the-Ground
- VEON 2Q25: Solid Digital Non-Telco Products Uplift, Kyivstar Listing in Focus
- [IO Technicals 2025/32] Bullish Momentum Builds
- Grab Holdings (GRAB US) - Harvesting Sequentially
- Micro-Mechanics (Holdings) Limited - Next Generation Supplier of the Semicon Industry
무료 미리보기 패스로 Smartkarma의 AI 증강 투자 인텔리전스 플랫폼을 탐색해보세요.
- 연구 요약 잠금 해제
- 최고의 독립 분석가를 팔로우하세요
- 개인화된 알림 수신
- 분석, 이벤트 등에 액세스
13조 달러 이상을 감독하는 세계 최고의 자산 관리자를 포함하여 55,000명 이상의 투자자와 함께하세요.
나중에 모든 기능에 액세스하려면 유료 플랜으로 업그레이드하세요.
or
Already have an account? Sign In Now
토론
(유료 플랜만)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
가격 차트(접속하기 위해 가입하세요)
- Kaken Pharmaceutical (4521 JP): Bleak FY26 Ahead, No Immediate Respite In Sight20 May 2025
- Kaken Pharmaceutical (4521 JP): Johnson Deal Is Good For Future, But For Now Bleak H2 Ahead06 Jan 2025
- Kaken Pharmaceutical (4521 JP): One-Off Payment Boosts H1FY25 Revenue; Headed for Another Bleak H226 Nov 2024
- Kaken Pharmaceutical (4521 JP): Key Operating Parameters Weakened in H1; H2 Not Seem to Be Better28 Nov 2023
- Kaken Pharmaceutical (4521 JP): Q1 Revenue Is Flat; Profit Falls; Bleak Outlook for FY2415 Aug 2023
- Kaken Pharmaceutical (4521 JP): H1FY23 Review- Key Drugs Continued to Fall; Guidance Reiterated16 Nov 2022
- Kaken Pharmaceutical (4521 JP): Falling Revenue of Top-Selling Drugs Limit Near-Term Growth Prospect09 Aug 2022
x